NFE2L2 and cancer: Our data suggest that targeted inhibition of miR-141-3p promoted Keap1 expression and suppressed Nrf2 expression and inhibited SLC7A11-GSH-GPX4, the downstream anti-ferroptosis pathway of Nrf2, in cancer cells.